KEK #No. |
Insel #No. |
Laufende Studien |
|
|
Kohorten |
143/15 |
- |
Congenital extrahepatic portosystemic shunts (Abernethy malformation): European Survey of current management strategies and clinical outcome. |
923/16 | - | Pro-Euro DILI Registry - Creation of a Multicentre and Multidisciplinary European Registry of Prospective Drug-Induced Liver Injury Cases (Pro-Euro-DILI). |
|
|
Leberkrebs |
111/15 |
2961 |
LILLY (REACH 2) : I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib” (Lilly). |
370/15 |
3034 |
Bristol-Myers Squibb Clinical Trial Agreement BMS CA209-459: A randomized, multi-center Phase Ill Study of Nivolumab versus Sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (CheckMate 459). |
0347/18 | 1898 | HCC Kohorte: Kohorten Studie mit Patienten die an einem hepatocellulären Karzinom erkrankt sind. |
275/17 | 3534 | Blueprint HCC: BLU-554-1101 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with HCC. |
1760/18 | 3805 | Axl S: sAxl as Diagnostic Biomarker of Steatosis- and Hepatitis Virus-Induced Hepatocellular Carcinoma. |
1585/18 | 3916 | CEUS: Kontrastmittel-verstärkter Ultraschall zur Beurteilung von fokalen Leberläsionen in Patienten mit Zirrhose oder anderen Risikofaktoren für ein Hepatocelluläres Carcinom (HCC). |
0400/19 | 4053 | MK3475-937: A Phase 3 Double-blinded, Twoarm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937). |
2392/18 | 4003 | Cosmic(Exelixis) (OASIS): XL184-312, a randomized, controlled phase 3 study of Cabozantinib (XL184) in combination with Atezolizumab versus Sorafenib in patients with advanced HCC who have not received previous systemic anticancer therapy. |
|
|
Virale Hepatitis |
922/16 |
- |
HBV-Kohorte. Schweizer Hepatitis B Kohorten Studie. SASL 37. |
338/14 |
2755 |
Abbvie M14-423: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II). |
0727/18 | 3715 | DAA and Cancer: Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of intra- and extrahepatic Malignancies in Patients with Chronic Hepatitis C. |
- | - | CMV T-Track. |
Metabolische Leberkrankheiten |
||
324/15 |
3042 |
Intercept 747-303 NASH (REGENERATE): A phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of obeticholic acid in subjects with nonalcoholic steatohepatitis NASH. |
1003/16 |
3225 |
GENFIT: Resolve-it: Genfit GFT505 in NASH phase 3: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of elafibranor in patients with non-alcoholic steatohepatitis NASH and Fibrosis (Emricasan). |
0294/18 | 3662 | Litmus - The European NAFLD Registry Liver Investigation: Testing Marker Utility in Steatohepatitis. |
0609/19 | 4067 | Litmus sub-study imaging: Litmus Sub-Study Imaging: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment and Validation of Imaging Modality Performance across the NAFLD Spectrum in a Prospectively Recruited Cohort. |
0980/19 | 4102 | NUT-3/NAS (Falk GmbH): Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH). |
0898/17 | 3942 | Aurora (Tobira) Allergan : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (TOBIRA). |
|
|
Zirrhose |
0548/17 | 3352 | GS-US-384-1944 Cirrhosis on NASH: A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Selonsertib in subjects with compensated cirrhosis due to nonalcoholic steatohepatitis, Stellar-4. |
- | - | NABEL Zirrhosen-Datenbank (Kanada und Bern). |
198/15 | 2854 |
Prosper: Phase IV observational hepatic encephalopathy +/- rifaximin. |
|
|
Vaskuläre Lebererkrankung |
213/13 |
2492 |
Valdig Konsortium zur Förderung des Studium von vaskulären Lebererkrankungen. |
|
|
Autoimmune Lebererkrankungen |
366/15 | 3004 | Intercept 747-302 Cobalt: A Phase 3b, double-blind, randomized, placebo-controlled, multicenter study evaluating the effect of obeticholic acid on clinical outcomes in subjects with primary biliary cirrhosis. |
1665/16 |
3272 |
SASL 38: Swiss Registry on Autoimmune Hepatitis. |
1666/16 |
3253 |
SASL 39: Swiss Registry on Primary Biliary Cholangitis. |
2236/16 | 3320 | SASL 40: Swiss cohort on Primary Sclerosing Cholangitis SWISS PSC. |
1508/18 | - | SASL 43: IgG4 Kohorte. Schweizer IgG4-bezogene hepato-biliäre Kranheit Kohorten Studie. |
1918/18 | 3952 | NUC-5-PSC (Navitas) Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary slerosing cholangitis. |
1968/17 | 3597 | Novartis CVAY736B2201. A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER). |
|
|
Andere |
1253/18 | 3720 | The Constans Study: A multi-center, multinational survey of NAFLD-related hospital visits: prevalence, severity, patterns of clinical practive and health-care costs. (Consultations for steatohepatitis). |
0604/19 |
4314 |
Untersuchung der Leberbeteiligung bei Patienten mit Alpha1-Antitrypsin-Mangel. |
487/18 | - | Combination of non-invasive Tests in chronic liver disease to improve a stage-targeted risk stratification and outcome prediction. |
|
|
Abgeschlossene Studien |
|
Liste |